Ocugen, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCGN research report →
Range $3.5 – $6
Price Chart
About the company
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis.
- CEO
- Shankar Musunuri
- IPO
- 2014
- Employees
- 116
- HQ
- Malvern, PA, US
Get TickerSpark's AI analysis on OCGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $260.55M
- P/E
- -3.84
- Fwd P/E
- 0.89
- PEG
- -0.84
- P/S
- 53.73
- P/B
- -14.52
- EV/EBITDA
- -4.61
- Div Yield
- 0.00%
- Gross Margin
- 88.53%
- Op Margin
- -1444.47%
- Net Margin
- -1367.61%
- ROE
- 643.95%
- ROIC
- -94.36%
Latest fiscal year · YoY change
- Revenue
- $4.41M+8.8%
- Gross Profit
- $2.02M-3.0%
- Op Income
- $-62,916,000
- Net Income
- $-67,846,000-25.5%
- EPS
- $-0.23-15.0%
- OCF Growth
- -35.2%
- FCF Growth
- -25.5%
- 52W High
- $2.73
- 52W Low
- $0.69
- 50D MA
- $0.90
- 200D MA
- $1.38
- Beta
- 2.04
- RSI (14)
- 43
- Avg Volume
- 7.28M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ocugen said Q3 was an execution quarter, with all three late-stage retinal gene therapy programs in Phase III, cash runway into 2028, and the first key readout expected from OCU400 in Q1 2027.· November 4, 2026
- All three late-stage modifier gene therapy programs are now in Phase III, with OCU400 expected to be the first to report top-line data in Q1 2027.
- OCU400 enrollment was completed in the Phase III liMeliGhT trial with 140 patients; the company also signed a Middle East/North Africa licensing deal and advanced access in the Bahamas.
- OCU410 moved into Phase III in September, while OCU410ST remains on track for top-line data in Q2 2027.
- Cash, cash equivalents, restricted cash and short-term investments were $84.6 million at September 30, 2026, and management said that supports runway into 2028.
- Quarterly losses narrowed on a per-share basis, but operating expenses were roughly flat year over year in Q3 and rose for the nine-month period.
Ocugen reported cash equivalents, restricted cash, and short-term investments of $84.6 million as of September 30, 2026, and said that cash runway should extend into 2028. Q3 2026 total operating expenses were $19.7 million, including $12.5 million of R&D and $7.2 million of G&A, versus $19.4 million in Q3 2025, including $11.1 million of R&D and $8.2 million of G&A. Q3 2026 net loss per common share was $0.01 versus $0.07 in Q3 2025. For the first nine months of 2026, total operating expenses were $57 million, including $34.4 million of R&D and $22.6 million of G&A, versus $50.5 million in the prior-year period; net loss per share was $0.14 versus $0.17. Forward-looking items: OCU400 top-line data is expected in Q1 2027, OCU410ST top-line data is expected in Q2 2027, management plans to complete OCU410 enrollment in 2027, and the company remains on track to file three BLAs by 2028.
Dr. Musunuri framed the quarter as one of execution and said Ocugen has moved all three late-stage programs into Phase III while expanding internationally through partnerships and a European presence. He emphasized the company’s modifier gene therapy platform as gene-agnostic and built for durable, one-time treatment benefit across multiple retinal diseases. His tone was confident and forward-looking, with repeated focus on near-term catalysts, especially the OCU400 data readout in Q1 2027 and the company’s stated plan to file three BLAs over the next three years.
Rita Johnson-Greene highlighted a cash position of $84.6 million as of September 30, 2026, which management said should fund runway into 2028 and cover two of the three late-stage programs through anticipated BLA filings. She reported Q3 operating expenses of $19.7 million, with $12.5 million in R&D and $7.2 million in G&A, compared with $19.4 million a year earlier. For the nine-month period, operating expenses were $57 million versus $50.5 million, and net loss per share improved to $0.14 from $0.17.
Analysts focused on Stargardt timing and what the DMC’s interim review meant. Management said the interim was pre-specified, based on a small and early cohort, and that the study remains blinded; they expect to review full 12-month data in 2027, then discuss results with the FDA before a pre-BLA meeting and filing. Questions also centered on the Bahamas LARTA pathway, where management said provisional approval could become full approval by year-end, the program is open globally, and pricing would match U.S. price. On OCU400, management reiterated that the Phase III trial was powered conservatively, with the team expressing high confidence in statistical significance at month 12.
The company now has three Phase III programs underway, giving investors multiple shots on goal across retinitis pigmentosa, Stargardt disease, and geographic atrophy. Management pointed to completed OCU400 enrollment, licensing revenue potential from the MENA deal, and a potential near-term commercial pathway in the Bahamas as evidence the platform is moving beyond pure development. They also reiterated runway into 2028, which reduces near-term financing pressure.
The call still depends on clinical readouts that have not yet arrived, especially OCU400 in Q1 2027 and OCU410ST in Q2 2027. Management acknowledged the Stargardt interim review was based on a small, early cohort with heterogeneous baselines, underscoring the risk that later data may be less clear than hoped. The Bahamas program is also still conditional/provisional, so the commercial upside discussed there is not yet fully de-risked.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.6%
- Shares Outstanding
- 339.31M
- Float Shares
- 334.50M
of shares held by institutions
160 13F filers
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for OCGN, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Chris JacobsHouse · NY27 | Sell | Nov 8, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 27.76M | ▲ 760.99K |
| State Street Corp | 19.55M | ▼ 1.92M |
| Vanguard Group Inc | 16.48M | ▲ 1.25M |
| Vanguard Capital Management LLC | 14.14M | ▼ 232.16K |
| Millennium Management LLC | 13.94M | ▲ 216.06K |
| Ubs Group AG | 9.56M | ▲ 4.38M |
| Geode Capital Management, LLC | 8.66M | ▼ 208.58K |
| Rtw Investments, LP | 6.67M | 0 |
| Ikarian Capital, LLC | 3.96M | 0 |
| Gmt Capital Corp | 3.51M | 0 |
| Vanguard Portfolio Management LLC | 3.38M | ▲ 47.18K |
| Northern Trust Corp | 2.75M | ▲ 2.03M |
Held by 142 ETFs
Biggest fund positions in OCGN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 9, 26 | Musunuri Shankar | sell | 468,727 |
| Oct 9, 26 | Musunuri Shankar | sell | 57,264 |
| Sep 9, 26 | Musunuri Shankar | sell | 468,727 |
| Sep 9, 26 | Musunuri Shankar | sell | 57,264 |
| Jun 15, 26 | Johnson-Greene Treerita Essalima | buy | 21,000 |
| Jun 11, 26 | Kompella Uday | other | 170,100 |
| Jun 11, 26 | Chandrasekhar Satishchandran | other | 170,100 |
| Jun 11, 26 | Castillo Kirsten | other | 170,100 |
| Jun 11, 26 | Zhang Junge | other | 170,100 |
| Jun 11, 26 | Coleman Blaise | other | 170,100 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OCGN coverage
Recent articles, reports, and earnings notes.
No research on OCGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OCGN report →Ocugen Eyes 2027 Trial Results and FDA Filing for Lead Gene Therapy
marketbeat.com · Nov 12
Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN
globenewswire.com · Nov 10
Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock Rises
zacks.com · Nov 5
Ocugen, Inc. (OCGN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Ocugen Q3 Earnings Call Highlights
marketbeat.com · Nov 4
Ocugen (OCGN) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 4
Ocugen Provides Business Update with Third Quarter 2026 Financial Results
globenewswire.com · Nov 4
Ocugen to Participate in Upcoming November Investor and Industry Conferences
globenewswire.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.